Martell Christopher 4
4 · Candel Therapeutics, Inc. · Filed Aug 2, 2021
Insider Transaction Report
Form 4
Martell Christopher
Director
Transactions
- Conversion
Series B Preferred Stock
2021-07-29−696,851→ 0 total(indirect: By LLC)→ Common Stock (283,514 underlying) - Conversion
Common Stock
2021-07-29+283,514→ 283,514 total(indirect: By LLC) - Purchase
Common Stock
2021-07-29$8.00/sh+125,000$1,000,000→ 125,000 total(indirect: By LLC)
Footnotes (3)
- [F1]These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a one-for-2.4579 basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series B Preferred Stock had no expiration date.
- [F2]Shares held by GTAM1 2012 ADV LLC, for which the Reporting Person serves as manager. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any.
- [F3]Shares held by GTAM1 2012 LLC, which is wholly owned by a trust for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any.